Organon & Co. (FRA:7XP)

Market Cap	1.79B -52.7%
Revenue (ttm)	5.29B -2.9%
Net Income	159.27M -78.4%
EPS	0.61 -78.4%
Shares Out	n/a
PE Ratio	11.22
Forward PE	2.32
Dividend	0.32 (4.71%)
Ex-Dividend Date	Nov 20, 2025

Volume	n/a
Average Volume	1,155
Open	6.34
Previous Close	6.37
Day's Range	6.34 - 6.79
52-Week Range	5.39 - 15.30
Beta	n/a
RSI	52.73
Earnings Date	Feb 12, 2026

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7XP

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Financial numbers in USD